about
Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytesBiological response modifiers in cancerTherapeutic vaccination with tumor cells that engage CD137.Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides.Novel approaches to therapeutic cancer vaccines.Silencing of the TGF-β1 gene increases the immunogenicity of cells from human ovarian carcinoma.Low-dose interferon-gamma-producing human neuroblastoma cells show reduced proliferation and delayed tumorigenicity.Immunotherapy of tumors with recombinant adenovirus encoding macrophage inflammatory protein 3beta induces tumor-specific immune response in immunocompetent tumor-bearing miceMultifunctional T Lymphocytes Generated After Therapy With an Antitumor Gallotanin-Rich Normalized Fraction Are Related to Primary Tumor Size Reduction in a Breast Cancer Model.Identification of an HLA-A*0201-restrictive CTL epitope from MUC4 for applicable vaccine therapy.Vaccination with liposome--DNA complexes elicits enhanced antitumor immunity.Melanoma differentiation-associated gene-7 (mda-7)/interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model.Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma.Efficacy of CD40 ligand gene therapy in malignant mesothelioma.Immunotherapy for murine K1735 melanoma: combinatorial use of recombinant adenovirus expressing CD40L and other immunomodulators.Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB.
P2860
Q24672952-FEECC081-C6C2-4F3D-A9E2-360C936412EAQ24685049-789CA403-57C4-40AB-A6E2-C601C8E40BFBQ35071688-0C616A0E-9D43-45A1-9155-9B4DDE167F17Q35160569-893C1219-C68C-420C-ABBF-AA3EBD82538BQ35623327-ADCC2D49-1C75-4F3E-9A39-0CDE4F242DA4Q35890860-9927686A-2313-4C78-9337-10B5619CE16CQ36694271-E03D1BAA-7D96-4B4B-B903-43D69C056B0EQ37728133-596555D3-8C47-496B-BEEA-B121A9D67AE4Q38848418-ABAF584E-0E24-42D4-AB56-6293FB9209D8Q39833293-B7E2CD62-7529-42F8-8770-C4D2E1D04D5FQ40255867-6837AD24-5BF3-4455-B7C3-905973BE2309Q40303380-DEB46220-0505-4518-9B75-A71B00D4C609Q40429655-408413F5-9030-46E8-A8DF-750FEB47B763Q40658312-12980F2A-5014-4375-9D54-243AA7932BE0Q44021835-7998574C-68C2-4A94-A0B8-A8BDDC3D7FE9Q45884692-CDDA2952-452F-4683-A1CD-9999401B0067
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Therapeutic vaccination for cancer.
@ast
Therapeutic vaccination for cancer.
@en
type
label
Therapeutic vaccination for cancer.
@ast
Therapeutic vaccination for cancer.
@en
prefLabel
Therapeutic vaccination for cancer.
@ast
Therapeutic vaccination for cancer.
@en
P356
P1433
P1476
Therapeutic vaccination for cancer.
@en
P2093
Pardoll DM
P304
P356
10.1006/CLIM.1999.4819
P433
P577
2000-04-01T00:00:00Z